- Home
- MDAI vs RVPH Comparison
MDAI vs RVPH Comparison
Compare MDAI & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- RVPH
- Stock Information
- Founded
- MDAI 2013
- RVPH 2006
- Country
- MDAI United States
- RVPH United States
- Employees
- MDAI N/A
- RVPH N/A
- Industry
- MDAI Medical/Dental Instruments
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- MDAI Health Care
- RVPH Health Care
- Exchange
- MDAI Nasdaq
- RVPH Nasdaq
- Market Cap
- MDAI 34.8M
- RVPH 36.7M
- IPO Year
- MDAI N/A
- RVPH N/A
- Fundamental
- Price
- MDAI $1.63
- RVPH $0.88
- Analyst Decision
- MDAI Strong Buy
- RVPH Strong Buy
- Analyst Count
- MDAI 2
- RVPH 5
- Target Price
- MDAI $4.75
- RVPH $9.00
- AVG Volume (30 Days)
- MDAI 276.1K
- RVPH 554.3K
- Earning Date
- MDAI 05-13-2025
- RVPH 05-15-2025
- Dividend Yield
- MDAI N/A
- RVPH N/A
- EPS Growth
- MDAI N/A
- RVPH N/A
- EPS
- MDAI N/A
- RVPH N/A
- Revenue
- MDAI $29,962,000.00
- RVPH N/A
- Revenue This Year
- MDAI N/A
- RVPH N/A
- Revenue Next Year
- MDAI $86.26
- RVPH N/A
- P/E Ratio
- MDAI N/A
- RVPH N/A
- Revenue Growth
- MDAI 55.21
- RVPH N/A
- 52 Week Low
- MDAI $0.82
- RVPH $0.49
- 52 Week High
- MDAI $3.25
- RVPH $4.28
- Technical
- Relative Strength Index (RSI)
- MDAI 65.66
- RVPH 47.68
- Support Level
- MDAI $1.57
- RVPH $0.85
- Resistance Level
- MDAI $1.73
- RVPH $1.15
- Average True Range (ATR)
- MDAI 0.10
- RVPH 0.11
- MACD
- MDAI 0.03
- RVPH 0.00
- Stochastic Oscillator
- MDAI 78.26
- RVPH 30.00
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.